A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors
Mechanism of Action
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to ERBB2, a protein found on the cell surface of certain tumors.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from the study agent
Location
Similar Trials
Yes
No
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.